iRhythm Appoints New President and Chief Executive

iRhythm Appoints New President and Chief Executive

King

Medical device service company iRhythm Technologies Inc.’s board of directors has appointed Kevin King to succeed Bill Willis as president, CEO and board member. King brings nearly three decades of experience in successive corporate leadership roles. Willis will remain with the firm to assist with the transition.

“Kevin is a seasoned CEO with a track record of success across the healthcare industry. His direct leadership experience in cardiology diagnostics and previous successes executing on complex service and IT business models will be of great value as we seek to continue to expand iRhythm’s business,” said William N. Starling, iRhythm’s chairman of the board. “Bill Willis did a tremendous job of leading the company from a revolutionary concept to a commercial company that has benefited more than 70,000 patients to date. We are excited to now bring in Kevin to lead us through this next stage of growth.”

King noted that there is “significant opportunity for rapid expansion,” for the 6-year-old company.
King most recently served as president and CEO of Affymetrix Inc., where he led a new growth strategy into the multi-billion dollar market for downstream validation and molecular diagnostics. Previously, King was president and CEO of Thomson Healthcare, an information services business focused on a range of healthcare-related companies. King has also held leadership roles at GE Healthcare, where he led a several-fold increase of the clinical systems business. He also held key leadership positions within Hewlett Packard’s Medical Products Group including in research and development, sales, marketing and business development.

King earned his bachelor’s from the University of Massachusetts and an MBA from New Hampshire College.

iRhythm provides diagnostic monitoring solutions that facilitate early diagnosis and treatment decisions, with the goal of ultimately improving patient health outcomes and reducing wasteful healthcare spending. Its flagship product, the Zio Patch, is designed to optimize and simplify the diagnosis of cardiac arrhythmias. The company is based in San Francisco, Calif.